Patient Recruitment Resumes in FibroGen, Inc. Phase 2 Study of Investigational Oral HIF-PH Inhibitor, FG-4592/ASP1517, for the Treatment of Anemia Associated with Chronic Kidney Disease

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced that patient recruitment has resumed in a phase 2 study of FG-4592/ASP1517, an investigational oral hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor in development for the treatment of anemia associated with chronic kidney disease (CKD).